Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript Summary
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript Summary
Adjusted EBITDA for Q3 was $33.1 million, up from $28.8 million the previous year, with an EBITDA margin of 35%.The following is a summary of the Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript:
以下是certara公司（CERT）2024年第三季度業績會電話會議記錄摘要：
Financial Performance:
財務表現:
Certara reported Q3 revenue of $94.8 million, an 11% increase year-over-year.
Software revenue was $35.9 million, which increased 15% over the prior year period.
Adjusted EBITDA for Q3 was $33.1 million, up from $28.8 million the previous year, with an EBITDA margin of 35%.
Adjusted diluted earnings per share for the third quarter were $0.13, up from $0.11 in Q3 2023.
Certara報告第三季度營業收入爲$9480萬，同比增長11%。
軟件營業收入爲$3590萬，較去年同期增長15%。
第三季度調整後的EBITDA爲$3310萬，較去年的$2880萬增長，EBITDA利潤率爲35%。
調整後的每股攤薄收益爲本季度$0.13，高於2023年第三季度的$0.11。
Business Progress:
業務進展：
Certara expanded its biosimulation capabilities with the acquisition of Chemaxon, enhancing its preclinical market reach.
Launched the new version 8.5 of Phoenix and integrated it with Certara Cloud for enhanced user experience.
Introduced the Certara Cloud platform, aiming to unify their software products and lower IT and security costs for customers.
Certara通過收購Chemaxon擴展了其生物模擬能力，增強了其臨床前市場覆蓋範圍。
推出了Phoenix最新的8.5版本，並與Certara Cloud集成，以提升用戶體驗。
推出Certara Cloud平台，旨在統一其軟件產品，降低IT和安防-半導體成本，以造福客戶。
Opportunities:
機會：
Certara's integration of AI capabilities post-Vyasa acquisition is set to improve data processing and scientific literature handling, enhancing software products.
Initiatives in expanding into the biotech market and focusing on large key accounts are expected to drive growth.
Certara在Vyasa收購後整合人工智能能力，旨在改善數據處理和科學文獻處理，進而加強軟件產品。
擴張生物科技市場並專注於大型主要客戶的舉措預計將推動增長。
Risks:
風險：
Experiencing a lengthened decision-making process among larger customers, making the company cautious about predicting second-half growth.
Divergence in growth between biosimulation and regulatory services, prompting a strategic review of the regulatory services business.
較大客戶間決策過程延長，使公司謹慎預測下半年增長。
生物仿真和監管服務增長出現分歧，促使對監管服務業務進行戰略評估。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
